CERS— CERUS CORP

Health Care$534M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	$233.8M+16.1%	$201.3M+7.8%	$186.8M-0.8%	$188.3M
Research and development	$67.7M+15.0%	$58.9M-12.9%	$67.6M+5.5%	$64.1M
Selling, general and administrative	$80.9M+6.6%	$75.9M+0.5%	$75.5M-9.4%	$83.3M
Restructuring	$3.7M	—	—	—
Total operating expenses	$148.6M+10.3%	$134.8M-8.2%	$146.9M-0.4%	$147.4M
Loss from operations	-$8.7M+39.0%	-$14.2M+52.7%	-$30.1M+11.8%	-$34.1M
Foreign exchange (loss) gain	-$1.3M-444.6%	$370K+157.1%	-$648K+6.1%	-$690K
Interest expense	-$8.3M+6.0%	-$8.9M-5.9%	-$8.4M-43.8%	-$5.8M
Other income, net	$3.0M+52.6%	$2.0M+12.0%	$1.8M+201.7%	-$1.7M
Total non-operating expense, net	-$6.6M-1.1%	-$6.5M+10.2%	-$7.3M+12.0%	-$8.3M
Loss before income taxes	-$15.3M+26.4%	-$20.8M+44.4%	-$37.3M+11.8%	-$42.3M
Provision for income taxes	$354K+72.7%	$205K-36.9%	$325K-33.4%	$488K
Net loss	-$15.6M+25.4%	-$21.0M+44.3%	-$37.6M+12.1%	-$42.8M
Net loss attributable to noncontrolling interest	-$10K+76.7%	-$43K+72.8%	-$158K-243.5%	-$46K
Net loss attributable to Cerus Corporation	-$15.6M+25.3%	-$20.9M+44.2%	-$37.5M+12.4%	-$42.8M
Basic	-$80+27.3%	-$110+47.6%	-$210+12.5%	-$240
Diluted	-$80+27.3%	-$110+47.6%	-$210+12.5%	-$240
Basic	$190.6M+3.3%	$184.6M+2.4%	$180.3M+2.1%	$176.5M
Diluted	$190.6M+3.3%	$184.6M+2.4%	$180.3M+2.1%	$176.5M
Product
Cost of revenue	$93.8M+16.2%	$80.7M+15.4%	$70.0M-6.7%	$75.0M
Gross profit	$112.3M+12.8%	$99.5M+15.2%	$86.4M-0.8%	$87.1M
Government Contract

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.